Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The first patient has been enrolled into Neurochem's European phase III clinical trial of Alzhemed, the company's investigational product candidate for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
The on-going European phase III clinical trial will investigate the safety and efficacy of Alzhemed in treating Alzheimer’s disease, with some 930 patients with mild-to-moderate forms of the disease expected to take part.
Patients will be randomized to receive either placebo or one of two different dose levels of Alzhemed for a period of 18 months, in addition to their regular treatment with one of a number of acetylcholinesterase inhibitors.
“Alzhemed’s good tolerability profile and unique mechanism of action aimed at stopping the progression of the disease rather than targeting the symptoms are particularly interesting,” said Dr Bruno Vellas, chairman of the Department of Internal Medicine and Geriatric Medicine, France.
Neurochem is also carrying out a phase III trial of the drug in North America, with the enrollment of 1,052 patients recently completed.